VRTX congressional trades
Vertex Pharmaceuticals Incorporated (VRTX) appears in 14 congressional disclosure rows from 7 members of Congress in 2025–2026 periodic reports: 6 purchases and 8 sales, with trade dates from May 3, 2024 to Aug 26, 2026. David Taylor reported the most, with 3 rows. The median gap between trade date and filing date is 35 days, and 6 trades were reported more than 45 days after it happened.
Rows keep the disclosed owner and amount range. This is a record of reported transactions, not a live VRTX portfolio or a trading signal.
- 14
- 7
- 6 / 8
- $56K – $315K
- sum of reported ranges
- 2026-08-26
Verified VRTX congressional disclosures
Parsed from official House Clerk and Senate eFD filings. This snapshot contains 6 purchases and 8 sales. Reported owners: Self, Spouse, Joint. Transaction dates run from 2024-05-03 to 2026-08-26.
| Politician | Trade date | Asset | Type | Owner | Amount | Filing |
|---|---|---|---|---|---|---|
| David Taylor | Vertex Pharmaceuticals Incorporated - Common Stock | Sale | Self | $1,001 - $15,000 | #20035392 Filed 2026-09-05 | |
| Alan Armstrong | Vertex Pharmaceuticals Incorporated - Common Stock | Purchase | Self | $1,001 - $15,000 | #fda235b3-bad7-4637-8fa1-053f354d929c Filed 2026-07-21 | |
| David Taylor | Vertex Pharmaceuticals Incorporated - Common Stock | Sale | Self | $1,001 - $15,000 | #20033916 Filed 2026-02-02 | |
| David Taylor | Vertex Pharmaceuticals Incorporated - Common Stock | Purchase | Self | $1,001 - $15,000 | #20030782 Filed 2025-09-02 | |
| Lisa McClain | Vertex Pharmaceuticals Incorporated - Common Stock | Sale | Spouse | $1,001 - $15,000 | #20030891 Filed 2025-08-13 | |
| Lisa McClain | Vertex Pharmaceuticals Incorporated - Common Stock | Sale | Spouse | $1,001 - $15,000 | #20030891 Filed 2025-08-13 | |
| Jefferson Shreve | Vertex Pharmaceuticals Incorporated - Common Stock | Sale | Self | $15,001 - $50,000 | #20030387 Filed 2025-06-22 | |
| Byron Donalds | Vertex Pharmaceuticals Incorporated - Common Stock | Sale | Self | $1,001 - $15,000 | #20029092 Filed 2025-04-14 | |
| Byron Donalds | Vertex Pharmaceuticals Incorporated - Common Stock | Sale | Spouse | $1,001 - $15,000 | #20029092 Filed 2025-04-14 | |
| Jefferson Shreve | Vertex Pharmaceuticals Incorporated - Common Stock | Purchase | Self | $15,001 - $50,000 | #20029038 Filed 2025-04-11 | |
| Jefferson Shreve | Vertex Pharmaceuticals Incorporated - Common Stock | Purchase | Self | $15,001 - $50,000 | #20027879 Filed 2025-03-09 | |
| Lisa McClain | Vertex Pharmaceuticals Incorporated - Common Stock | Purchase | Spouse | $1,001 - $15,000 | #20030891 Filed 2025-08-13 | |
| Julia Letlow | Vertex Pharmaceuticals Incorporated - Common Stock | Purchase | Self | $1,001 - $15,000 | #20030977 Filed 2026-01-13 | |
| Tommy Tuberville | Vertex Pharmaceuticals Incorporated - Common Stock | Sale | Joint | $1,001 - $15,000 | #0a25588d-a3f8-4ed6-971a-706097f78e3a Filed 2026-08-05 |
A filing can describe the member, a spouse, a dependent, or a joint asset. Amounts are statutory ranges, not execution prices. See how to read congressional stock-trade disclosures before treating a delayed row as a trading signal.
VRTX disclosures by member
| Member | Rows | Buys | Sells | Last trade |
|---|---|---|---|---|
| David Taylor's VRTX trades | 3 | 1 | 2 | 2026-08-26 |
| Jefferson Shreve's VRTX trades | 3 | 2 | 1 | 2025-05-12 |
| Lisa McClain's VRTX trades | 3 | 1 | 2 | 2025-06-11 |
| Byron Donalds | 2 | 0 | 2 | 2025-03-20 |
| Alan Armstrong | 1 | 1 | 0 | 2026-03-27 |
| Julia Letlow | 1 | 1 | 0 | 2024-10-23 |
| Tommy Tuberville | 1 | 0 | 1 | 2024-05-03 |
How long disclosure took
Days from trade date to filing date for 14 rows. The STOCK Act allows 30 days from notification and no more than 45 days from the trade. A late row is a timing fact, not evidence of wrongdoing.
- 0–15 days
- 3
- 16–30 days
- 4
- 31–45 days
- 1
- Over 45 days
- 6
- Median / longest
- 35d / 824d
Source documents
11 House Clerk and Senate eFD periodic transaction reports, newest first. Each link opens the official filing.
- #20035392Filed 2026-09-05 · 1 row
- #0a25588d-a3f8-4ed6-971a-706097f78e3aFiled 2026-08-05 · 1 row
- #fda235b3-bad7-4637-8fa1-053f354d929cFiled 2026-07-21 · 1 row
- #20033916Filed 2026-02-02 · 1 row
- #20030977Filed 2026-01-13 · 1 row
- #20030782Filed 2025-09-02 · 1 row
- #20030891Filed 2025-08-13 · 3 rows
- #20030387Filed 2025-06-22 · 1 row
- #20029092Filed 2025-04-14 · 2 rows
- #20029038Filed 2025-04-11 · 1 row
- #20027879Filed 2025-03-09 · 1 row
What VRTX filings don’t tell you
A disclosure row records a trade date, an amount bracket, and who owned the asset. It does not say why the trade was made, whether the position is still held, or anything about the business behind the ticker: revenue trends, margins, balance-sheet risk, or valuation. Those answers are in company filings, not congressional ones.
- Vertex Pharmaceuticals Incorporated financials and filings
Audited SEC figures, what moves VRTX, and primary sources.
Compare LLY vs VRTX side by side
To work through a company yourself, use our stock research checklist. Members get the full version of that work: one sourced investment call a month, with the numbers and the risks that would change the view.
Members-only research
What members are reading this month
- NVIDIA’s growth has a financing bill
Sales up about 18% on the prior quarter, receivables up about 55%, supply commitments at $279 billion. What NVIDIA’s financing bill means for the price you pay.
- Citadel bought the AI fire sale. The seller had run out of time.
Up 439% in the first half, down about 67% in July: how an AI hedge fund ended up selling a roughly $16 billion stock book to Citadel at a discount.
The thesis, the numbers behind it, and what would break it. Full access is $39 a month.
Read the full researchRelated research
VRTX congressional trades — FAQ
Who in Congress traded VRTX?
House Clerk and Senate eFD periodic reports for 2025 and 2026 contain 14 verified VRTX rows from 7 members: Alan Armstrong, Byron Donalds, David Taylor, Jefferson Shreve, and 3 other members. Image-only filings are excluded, and this is not a live brokerage statement.
Does this page show current VRTX holdings?
No. STOCK Act filings disclose reportable transactions after the fact, usually within 45 days, as amount ranges and owners. They do not prove a current position, an exact share count, or why the trade happened.
Why are VRTX amounts shown as ranges?
Congressional periodic transaction reports use statutory value bands such as $1,001 - $15,000; $15,001 - $50,000. Yield Theory keeps those ranges instead of inventing a midpoint, exact trade size, or return.
How complete is VRTX congressional-trade coverage?
This snapshot covers every machine-readable House and Senate periodic transaction report for 2025 and 2026 (176 members). Image-only House filings and paper Senate filings are not included, so missing rows are not proof that no other lawmaker traded VRTX.
Yield Theory is not affiliated with any elected official. This page uses the 2025–2026 House Clerk and Senate eFD periodic report snapshot generated 2026-10-06. It is not a complete lifetime portfolio, a performance track record, or investment advice.
A disclosure is not a thesis.
This page shows who reported VRTX and in what range. Membership is the monthly sourced call, plus a five-minute check when the evidence moves. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included